# Progress Note 05 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Friedrich Nietzsche (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI019-SYN-TD
- Date: 1881-09-01
- Fictional facility: St. Posthumous Health Center
- Fictional author: Konrad Ellison-Mbatha, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Mr. Nietzsche is a 36-year-old writer with chronic migraine on galcanezumab, recovering from medication overuse headache after a three-week taper of a butalbital combination, and with pathologic myopia of the right eye and a recent posterior vitreous detachment, who comes for his preventive visit two weeks after his four-week review. He has had headache on 4 days in the past two weeks, 2 of them with migraine features, treated with sumatriptan or naproxen. His second galcanezumab injection, given two weeks ago, caused only mild redness at the site. The floaters in his right eye are fading and he has had no new flashes. He sleeps about five and a half hours and has started the insomnia program. He has not had a tetanus booster for more than ten years and has never been tested for HIV or hepatitis. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 36 |
| Headache | 4 headache days in two weeks, 2 with migraine features |
| Eye | Floaters fading; no new flashes or shadow |
| Mood | PHQ-2 1 |
| Medicines | Galcanezumab 120 mg monthly; sumatriptan 100 mg or naproxen 500 mg with metoclopramide 10 mg as needed |

## Health risk assessment

Completed by the patient on paper, in large print, in the waiting room and reviewed with him by Dr. Ellison-Mbatha. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair, and better than at the start of the summer |
| Psychosocial | Lives alone and spends most of the day alone, which he prefers for his work; writes to several close friends; small pension |
| Alcohol | A glass of wine a few times a month; AUDIT-C 1 at intake |
| Tobacco | Never |
| Physical activity | Walks five to seven hours a day in the mountains |
| Nutrition | Simple meals at fixed times; little meat; fruit and vegetables most days; has kept regular meals since intake |
| Sleep | About five and a half hours; CBT-I started |
| Safety at home | Feels safe; no firearms |
| Sun and altitude | Wears sunglasses and a brimmed hat on long walks |
| Activities of daily living | Independent |
| Hearing and vision | No hearing difficulty; reads with the left eye, with contact lenses |
| Oral health | Dental visit last winter |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, weight loss or night sweats |
| Eyes | Positive | Fading floaters in the right eye; no new flashes, shadow or loss of vision |
| Ears, nose, mouth, and throat | Negative | No hearing loss or sore throat |
| Cardiovascular | Negative | No chest pain or palpitations, including after sumatriptan |
| Respiratory | Negative | No cough or breathlessness on long climbs |
| Gastrointestinal | Positive | Occasional constipation, no worse since starting galcanezumab; no abdominal pain or blood in the stool |
| Genitourinary | Negative | No urinary symptoms |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rash; injection sites healed |
| Neurological | Positive | Four headache days in two weeks; no weakness, numbness or new pattern |
| Psychiatric | Negative | Mood steady; PHQ-2 1 |

11 systems reviewed. **S**

## Current medications

- Naproxen 500 mg oral tablet, one tablet with food at the start of a migraine attack, may repeat once after 12 hours; no more than two days a week **S**
- Metoclopramide 10 mg oral tablet, one tablet with the acute medicine when a migraine attack brings nausea or vomiting; no more than two days a week **S**
- Galcanezumab 120 mg/mL auto-injector, 240 mg (two injections) under the skin as a first loading dose, then 120 mg once a month, for chronic migraine prevention **S**
- Sumatriptan 100 mg oral tablet, one tablet early in a migraine attack, may repeat once after 2 hours; no more than two days a week and no more than eight days a month **S**

## Allergies

- No known allergy **S**

## Objective

BP 112/70 mmHg; pulse 62 bpm; respirations 14/min; temperature 36.5 °C; oxygen saturation 98% on room air; weight 66.8 kg; BMI 22.1 kg/m². All vital signs are synthetic.

PHQ-2: 1. All results are synthetic.

## Immunizations given today

- Tdap vaccine; last tetanus booster more than ten years ago **S**
- Hepatitis B vaccine (HepB-CpG), first of two doses **S**
- Influenza vaccine, inactivated, trivalent, preservative free, for the coming season **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Lean and well; weight 66.8 kg, BMI 22.1; blood pressure 112/70; pulse 62 and regular |
| Eyes | Wearing contact lenses; right pupil about 1 mm larger than the left in light and dark, both reacting briskly; no ptosis; eye movements full |
| Neck | No thyroid enlargement or nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation |
| Abdomen | Soft and non-tender |
| Skin | No suspicious lesions; injection sites on the abdomen healed |
| Neurological | Normal |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated. Low cardiovascular risk: normal blood pressure, normal weight, no smoking or diabetes; formal risk assessment and lipid testing begin at 40 unless risk factors appear. **S**
   - HIV, hepatitis C and hepatitis B tests drawn today with his agreement.
   - Tdap, the first hepatitis B vaccine dose and the influenza vaccine today.
   - Next preventive visit in one year.
2. **Chronic migraine without aura on galcanezumab** (G43.709). Fewer headache days since the taper and the first two injections; acute medicine within limits. **S**
   - Third galcanezumab injection at the eight-week review.
   - Continue the diary.
3. **Posterior vitreous detachment, right eye** (H43.811). Floaters settling, with no new symptoms. **S**
   - Repeat dilated examination at the eight-week review, as planned.
   - Same-day eye care for any new shower of floaters, flashes or shadow.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 112/70 mmHg |
| Lipid screening and cardiovascular risk | Not indicated | Statin risk assessment is recommended from 40; no risk factors |
| Diabetes screening | Not indicated | Recommended at 35 to 70 for adults with overweight or obesity; BMI 22.1 |
| Colorectal cancer screening | Not indicated | Begins at 45; no family history known |
| HIV screening | Ordered | Once for all adults; drawn today |
| Hepatitis C screening | Ordered | Once for all adults; drawn today |
| Hepatitis B screening | Ordered | Triple panel once for all adults; drawn today before the first vaccine dose |
| Syphilis testing | Up to date | Treponemal antibody and RPR nonreactive at the consultation; repeat only with new exposure |
| Depression screening | Completed today | PHQ-2 1 |
| Unhealthy alcohol use | Up to date | AUDIT-C 1 at intake |
| Tobacco use | Not indicated | Never used tobacco |
| Eye examination | Up to date | Comprehensive dilated examination six weeks ago; yearly for pathologic myopia |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap today; last booster more than ten years ago |
| Hepatitis B vaccine | Completed today | First of two HepB-CpG doses today; second in one month |
| Influenza vaccine | Completed today | Inactivated vaccine for the coming season |
| COVID-19 vaccine | Declined | Discussed as an individual decision; he chose not to have it this season |
| HPV vaccine | Not indicated | Routine through 26; no new exposure risk at 36 |
| Zoster vaccine | Not indicated | Recommended from 50 |

## Advance care planning

Voluntary advance care planning discussion of about 16 minutes, with his consent. He named a health care agent, a close friend with whom he corresponds, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. He said that what matters most to him is being able to think clearly, to read and write, and to walk. He chose not to record specific treatment preferences today. The plan will be revisited yearly or after any serious illness. **S**

## Guideline basis

- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice (2021), American Headache Society (Headache 2021;61(7):1021-1039)
- Sexually Transmitted Infections Treatment Guidelines, 2021 (2021), Centers for Disease Control and Prevention (MMWR Recommendations and Reports 2021;70(4):1-187)
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication (2022), U.S. Preventive Services Task Force
- Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Eight-week review in two weeks, with the third galcanezumab injection and the repeat dilated eye examination. HIV, hepatitis C and hepatitis B results by phone. Second hepatitis B vaccine dose in one month. Next preventive visit in one year. **S**
- Next scheduled visit 1881-09-15: eight-week review of prevention: headache days, disability, mood, sleep and the plan ahead. **S**
